The DOI matches its Crossref record.
Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies
Abstract
Many data point to a pathogenetic role for IgM antibodies to the myelin-associated glycoprotein (MAG) in the neuropathy associated with IgM monoclonal gammopathy, supporting the use of immune therapies in affected patients. Almost 50% of patients have been reported to improve with these therapies, but the effect of treatment on the long-term prognosis of the neuropathy remains unclear. We analysed the outcome of 25 of the 26 patients (mean age at entry 65 years, range 45-85 years) with neuropathy and high anti-MAG IgM, first examined by us between 1984 and 1994. By January 1999, after a mean follow-up of 8.5 years (range 2-13 years) and a mean duration of neuropathy symptoms of 11.8 years (range 3-18, >10 years in 16), 17 patients (68%) (aged 58-84 years, mean 73.4) were alive, while eight (32%) (aged 69-78 years, mean 73.1) had died 3-15 years (mean 10.6) after neuropathy onset; in none of them was death caused by the neuropathy, although in three it was possibly related to the therapy for the neuropathy. By the time of last follow-up or patients' death, 11 patients (44%) were disabled by severe hand tremor, gait ataxia or both. The disability rates at 5, 10 and 15 years from neuropathy onset were 16, 24 and 50%, respectively. Of the 19 patients treated during the follow-up for 0.5-11 years (mean 4 years) with various immune therapies, five reported a consistent and four a slight improvement in the neuropathy (total 47%) after one treatment or more, but in only one patient was improvement persistent throughout, to the end of follow-up. In 10 patients (53%), severe adverse events, possibly related to therapy, occurred during treatment and were considered responsible for the patient's death in three. The neurological impairment did not differ between treated and untreated patients at the end of a similar follow-up. Our findings indicate that (i) the majority of patients with neuropathy and anti-MAG IgM have a favourable prognosis even after several years, and (ii) current immune therapies, though temporarily effective in half of the patients, are associated with considerable side effects which limit their prolonged use and efficacy, suggesting that until more effective or safer therapies become available, they should probably be reserved for patients impaired in their daily life or in a progressive phase of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Peripheral neuropathies and anti-glycolipid antibodies
Willison, H. J. (2002) · Brain · doi:10.1093/brain/awf272 · Cited by 710
Chronic Inflammatory Demyelinating Polyneuropathy
Köller, H., Kieseier, B. C., Jander, S., & Hartung, H.-P. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041347 · Cited by 511
Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype
Mathey, E. K., Park, S. B., Hughes, R. A. C., Pollard, J. D., Armati, P. J., Barnett, M. H., Taylor, B. V., Dyck, P. J. B., Kiernan, M. C., & Lin, C. S.-Y. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-309697 · Cited by 440
Clinical spectrum of chronic acquired demyelinating polyneuropathies
Saperstein, D. S., Katz, J. S., Amato, A. A., & Barohn, R. J. (2001) · Muscle & Nerve · doi:10.1002/1097-4598(200103)24:3<311::aid-mus1001>3.0.co;2-a · Cited by 417
Dalakas, M. C., Rakocevic, G., Salajegheh, M., Dambrosia, J. M., Hahn, A. F., Raju, R., & McElroy, B. (2009) · Annals of Neurology · doi:10.1002/ana.21577 · Cited by 312
Metadata
- Authors
- Nobile-Orazio, E.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-04-01
- Volume
- 123
- Issue
- 4
- Pages
- 710-717
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2096755516
- Cited by
- 237
- References
- 0
- FWCI
- 6.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. https://app.cochat.ai/papers/10.1093/brain/123.4.710
- The paper
- Nobile-Orazio, E. (2000). Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain. https://doi.org/10.1093/brain/123.4.710
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.